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sis. were not associated with the incidence of left atrial appendage thrombus. 
Conclusions: Maintenance hemodialysis patients have left atrial appendage thrombus at 
an unexpectedly high Incidence. The chronic use of antiplatelet drugs and the concomi- 
tant presence of diabetes mellltus and a low hematocrit may be Involved in left atrial 
appendage thrombus form&on. 
1008-i 30 Comparison of Echocardiographic Indices of Right 
Ventricular Obstruction in Pulmonary Embolism 
Nicolas Mansencal, Thierry Joseph, Antoine Vieillard-Baron. Salah D. Qanadli, Fran~o~s 
Jardin. Pascal Lacombe, Gutllaume Jondeau, Olivier Dubourg, H&pita1 Ambrolse Par& 
Boulogne. France 
Background: Different echocardiographlc parameters have been described in pulmonary 
embolism (PE). The ouroose of this studv was to determine the most accurate echocar- 
dlographic index of right ventricular obstruction in acute PE. 
Methods: Fiftv-seven consecutive oatients (mean aae 56 * 17 vears) oresentlno with PE 
I  ,  , .  
quantified by angiographic Miller index were studied. Following echocardiographic 
parameters were systematically assessed: 1) right to left ventricular end-dlastollc diame- 
ter ratlo (RVEDD/LVEDD) in parasternal long-axis view, 2) right to left ventricular end- 
diastolic area ratio (RVEDAILVEDA) in apical 4-chamber view, 3) systolic pulmonary 
arterial pressure @PAP) using CW Doppler. 
Results: The correlations between echocardiography and Miller Index were 0.52 for the 
AVEDD/LVEDD, 0.72 for the RVEDA/LVEDA and 0.52 for SPAP. Using Miller index 
higher than 40% to define massw PE with echocardiographic disorders, the cut-off val- 
ues of the RVEDD/LVEDD, the RVEDA’LVEDA and SPAP that yielded the highest dis- 
cnminating power were 0.5, 0.6 and 35 mmHg respectively, according to ROC curves. 
Echocardiographlc ROC curves analysis showed that the RVEDAILVEDA was the more 
accurate indicator of right ventricular obstruction. 
Conclusion: This echocardiographic study suggests that the right to left ventricular end- 
diastolic ratio using apical four-chamber view is the most accurate echocardiographic 
parameter of right ventriculal obstruction in acute PE. with a ratio higher than 0.6. 
1008-i 31 Bosentan Increases Warfarin Dosing Requirements in 
Pulmonary Hypertension 
Matthew P~ncus, Carolyn Corngan, Peter Macdonald. Christouher S. Havward, Anne 
Keogh, St. Vincent’s Hospital, Sydney, Australia 
Background: Bosentan is the first oral agent to have proven effectiveness in pulmonary 
arterial hypertension. Warfarin also has proven benefits and is used in most patients with 
this condition. Data from a trial in healthy volunteers have suggested that bosentan can 
reduce prothrombin time in those taking warfar~n. This is the first study examining the 
effect of bosentan on the International Norm&sing Ratlo (INR) in any patient population. 
Methods: A retrospective observational study was performed of 19 wadarinised patients 
wth pulmonary hypertension who had been enrolled in an open label bosentan study. 10 
of the patients had primary pulmonary hypertension, 4 had chronic thromboembollc pul- 
monary hypertension, 3 had scleroderma and 2 had systemic lupus erythematosis. Their 
mean age was 40 years. The patients had their INR and warlarin dose recorded at base- 
line, after a month of bosentan at a dose of 62.5 mg twice daily, and after an additional 
month at a dose of 125 mg twice daily.Warfar!n doses were adjusted at the discretion of 
the patients’ general practitioners with a target range of 2.3. 
Results: There was an increase in the mean wadarin dose from 3.6 (SD 1.4) to 4.4 (SD 
1.5) after a month on the low bosentan dose and a further increase to 4.6 (SD 1.5) after a 
month on the higher dose. This increase was statistically significant (p<O.Ol). The corre- 
spondmg INRs were 2.5 at baseline, 2.6 after 1 month and 2.5 after 2 months. These 
were not significantly different. 
Conclusion: When warfarinised patients with pulmonary hypertension are starled on 
bosentan, they require a higher dose of waiiarin to maintain a steady INR. 
1008-l 32 The Utility of Sildenafil in Infants With Pulmonary 
Hypertension 
P. V. Suresh A. Varma, R. Sharma, C. John, Sunita Maheshwari, Narayana -I 
Hrudayalaya, Bangalore, India 
Background: The treatment of pulmonary artery hypertension (PAH) has been limited by 
the paucity of effective and affordable oral therapy. The use of sildenafil in adults with 
PAH has been reported. However, its efficacy in the pediatnc population has not been 
fully evaluated. We used It as a last resort in 3 infants with pulmonary hypertension and 
the results are reported. 
Methods: Infants with PAH unresponsive to conventional therapy available at our center 
were considered for sildenafil therapy. Parental consent was obtained in accordance with 
the hospital protocol for Investigational drugs. The clinical status and echocardiographic 
indicators of PAH such as tricuspid regurgitation (TR) jet gradient and the direction of the 
patent ductus arteriosus (PDA) were assessed. As we were using an investigational drug 
as a ‘last-ditch’ effort, cardiac catheterization data was not obtained. Sildenafil was 
started and echo evaluation repeated at 24 hours, 46 hours and 1 week. 
Results: Between March to August 2002, 3 infants at our institution had severe PAH 
requiring therapeutic intervention. The age range was 15 days to 9 months and weight 
was 2.5 to 6.5 kg. The diagnoses included a postoperative PDA ligation (n=l) and 2 
infants with persistent primary pulmonary hypertension with no identifiable cardiac 
cause. In 2 infants the TR jet gradient decreased from 75.60 to 20-30 mmHg within 24 
hours of starting sildenafil, and the patients were rapidly weaned off the ventilator and 
oxygen. In the 9 month old no response was noted initially or at 1 week. 
Conclusion: Oral sildenafil appears to be especially effective in neonates with pulmonary 
hypertension. If it works, the effect appears to be dramatic and occurs within 24-46 
hours. Further prospective trials to assess its effect, and decide on dosing schedules, are 
needed. 
1008-l 33 Survival After Diagnosis of Primary Pulmonary 
Hypertension: Single Center Experience With 
Transplantation and Preoperative Therapy With 
Prostacyclin Analogues 
Michael Dandel Dagmar Kemper, Yuguo Weng, Sead Mulahasanovic, Hans B. 
Lehmkuhl, Bernhard Schulz, Martin Bettmann, Susanne Kapell, Heidrun Bbttcher, 
Manfred Hummel, Roland Hetzer, Deutsches Herzzentrum Berlin, Berlin, Germany 
Background: Without treatment, patients with primary pulmonary hypertension (PPH) 
survive less than 3 years after diagnosis. Our study summarized over 11 years clinical 
experience in PPH therapy. 
Methods: We reviewed our institution’s experience with both transplantation (TX) and 
preoperative prostanoid therapy. The analysis included all PPH patients (56 women, 27 
men) referred by our institution for TX between 1991 and 2002. TX was performed in 36 
of these patients (21 heart-lung and 15 double-lung TX). Since 1996 we used a stepwise 
therapeutic regimen which included beraprost tablets or iloprost inhalation !n the earlier 
stages of the disease and intravenous iloprost infusion in NYHA class IV patbents. 
Results: The actuarial survival since diagnosis for all 85 evaluated patients was 90.5% at 
1 year, 69.4% at 3 years, 62.5% at 10 years, and the mean suwival time since diagnosis 
was 138 * 17 months. Of these patients, only 15 underwent neither vasodilator therapy 
with prostanoids (for various reasons) nor transplantation (8 patients died before TX, 7 
are still on the waiting ltst). The other 70 were treated with prostanoids or with transplan- 
tation or with both. The actuarial suwival after PPH dtagnosis in this group reached 
74.1% at 3 years and 66.7% at 10 years. The 3 year actuarial survival since diagnosis 
was 76.4% in patients treated preoperatively with prostanolds and 56.25% in those with- 
out prostanoids. The mortality rate on the waiting list for TX was 11.5% in the prostanoid 
group and 26.1% in the group without prostanoid treatment. The actuarial post-transplant 
suw~val was 44.5% at 5 years and 42.9% at 8 years. At the present time, 27 patients are 
being treated with prostanoids. Listing for transplantation could be postponed during this 
treatment of 25.2 f 12.6 months duration in 26 patients, although the mean time since 
diagnosis reached already 56.0 254.4 months. 
Conclusions: Since use of prostanolds increases the 3.year actuarial SUIVIV~I after PPH 
diagnosis and reduces the mortality rate on the waiting list, it is an effective bridging-to- 
transplant therapy. Transplantation in combination with prior prostanoid administration 
provides important su~~val benefits for PPH patients. 
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1009-117 Clopidogrel Nonresponders Discovered During Point- 
of-Care Platelet Aggregation Testing 
Wet C. Lau Charlene J. New. Paul B. Watkins, David G. Carville, Kirk E. Guyer, Eric R. 
Bates, University of Michigan Health System, Ann Arbor, MI. Indiana Unwersity, South 
Bend, IN 
Background:The phenomenon of aspirin resistance has recently been recognized. Dur- 
ing the course of determlning that cytochrome P450 (CYP) 3A4 is the primary catalyst for 
the metabolic activation of the prodrug clopidogrel, it was obsewed that the effectiveness 
of a loading dose of clopidogrel varied I” healthy volunteers. 
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Methods: Platelet aggregation was measured with the point-of-care MICROSTM cell 
counter (ABX Dlagnostcs, Irvine, CA) and the PlateletworksTM test platform (Helena Lab- 
oratories, Beaumont TX) using 20 FM ADP agonist in 20 human healthy volunteers 
before any drug administration (0 hours) and 4 hours following clopidogrel 450 mg oral 
administration. Subjects with percent platelet aggregation -> 70% at 4 hours after clop~. 
dogrel administration were considered to be non-responders. Subjects with percent 
platelet aggregation c 70% at 4 hours after clopidogrel administration were considered to 
be responders. In viva CYP3A4 activity at baseline and 4 hours after clopidogrel was 
measured by the erythromycin breath test. Results were compared using a two group t- 
test. 
Results: Twenty-five percent (5120) of the subjects did not respond to a loading dose of 
clopidogrel. Platelet aggregation was significantly higher in the non-responders as com- 
pare with the responders 4 hours after clopidogrel administration (80 f 9% vs. 37 _+ 20%, 
p=O.O002). The metabolic activity of CYP3A4 in the clopidogrel non-responders was 
lower than in the responders (1.9~ 0.7% vs. 2.7$1.0 % “c0, exhaled/hour, ~~0.15). 
Conclusion: This study demonstrates that clopldcgrel non-responders exist and that 
they have lower metabolic activity of CYP3A4. These results, in addition to our previous 
observation that atorvastatin and potentially other CYP3A4 substrates attenuate the 
platelet inhibitory activity of clopidogrel, amplifies the importance of determining whether 
platelet aggregation inhibition targets are being met in individual patients by point-of-care 
platelet aggregation testing. 
1009-118 Effects of Clopidogrel-Aspirin Combination Versus 
Aspirin Alone on Platelet Aggregation and Major 
Receptor Expression in Patients With Heart Failure: For 
the Plavix Use for Treatment of Congestive Heart 
Failure (PLUTO-CHF) Trial 
Victor L. Serebruany, Alex I. Malinin, Scott D. Jerome, David R. Lowry, Athol W. Morgan, 
David C. Sane, Christopher M. O’Connor, Sinai Hospital, Johns Hopkins University, 
Baltimore, MD, Duke Clinical Research Institute, Durham, NC 
Background: Persistent platelet activation may contribute to thrombotic events in patients 
with congestive heart failure (CHF). Chronic use of platelet inhibitors could therefore rep- 
resent an independent avenue to improve morbidity, mortality, and quality of life in this 
expanding population. We assessed antiplatelet propelties of clopidogrel with aspirin 
(C+A) versus aspirin alone (A) in CHF patients with heightened platelet activity. 
Methods: Patients with LVEF < 40%, or CHF symptoms in the setting of preserved sys- 
tolic function and NYHA Class II-IV were screened. Patients were considered to have 
platelet activation when 4 out of the following 5 parameters were met: ADP- induced 
platelet aggregation>60%; collagen-induced aggregation >70%; whole blood aggrega- 
tionzl8 ohms: expression of GP Ilb/llla> 220 log MFI; and P-selectin cell positivity > 8%. 
All patients received aspirin 325 mg for at least a month prior to screening. Patients were 
randomly assigned to C+A (n=25), A (n=25) groups, or represent screen failures (n=36). 
Platelet studies were performed at baseline and after 30 days of therapy. 
Results: There were no deaths, hospitalizations, or serious adverse events. There were 
no changes in platelet parameters in the A group. In contrast, therapy with C+A resulted 
in a significant inhibltion of platelet activity assessed by ADP- (p=O.OOOOl), and epineph- 
rine-induced (p=O.O016) aggregation, closure time (p=O.O4), expression of PECAM-1 
(p=O.O09). GP lb (p=O.O06), GP Ilb/llla antigen (p=O.OOOl), GP Ilb/llla activity with PAC- 
1 (p=O.O021), CD151 (p=O.O026) when compared with A group. Therapy with C+A also 
resulted in the reduced formation of platelet-leukocyte microparticles (p=O.O21). Col- 
lagen-induced aggregation in plasma and in whole blood, expression of vitronectin 
receptor, P-se&tin, CD63. CD107a, and CD107b did not differ between groups. 
Conclusion: Treatment with C on top of the ASA provides greater inhibition of platelet 
activity than aspirin alone in CHF patients. Patients with CHF exhibiting heightened 
platelets represent a potential target population in which addition of clopldogrel may 
decrease mortality by reducing incidence of thrombotic vascular events. 
1009-l 19 Whole Blood Aggregometry as s Potential Method of 
Detecting Aspirin Resistance 
James J. Nawarskas Joe R. Anderson, Veena Raizada, University of New Mexico 
Health Sciences Center, Albuquerque, NM 
Background: Much attention has currently being given to the phenomenon of aspirin 
resistance as a potential cause of therapeutic failure for patients taking this agent. 
Despite this attention, llttle is known regarding factors that may predispose to asplrin 
resistance and how to identify aspirin-resistant patients. 
Methods: We studied 13 healthy volunteers (mean + s.d. age = 25.5 + 5.9 years) in an 
open-labeled study. Each subject received a single oral 325 mg dose of aspwn. Blood 
samples were drawn at 0, 5. 10, 15, 20, 25, 30, 45, 60, 75, and 90 minutes and at 2, 4, 6, 
8, 12, 24, 48, and 72 post-dose to determine the onset of duration of aspirin effect. Plata- 
let aggregatton was assessed at each time point using whole blood impedance aggrego- 
metry with collagen (I .O mcg/mL) and arachldonlc acid (0.5 mM) as pro-aggregants. The 
onset of aspirin affect was defined as at least 25% inhibition of aggregation compared to 
baseline. The duration of aspirin effect was defined as a return of platelet aggregation to 
75% of baseline. 
Results: The onset of aspirin effect was within 30 minutes for 9 subjects and within 90 
minutes for all subjects in response to collagen. In response to arachidonic acid, the 
onset of affect was within 30 minutes for 12 subjects and within 45 minutes for all sub- 
jects. By 24 hours, the aspirin effect had worn off in 2 subjects in response to collagen 
and in 2 additional subjects by 48 hours post-dose. Inhibition of platelet aggregation in 
response to arachidonic acid persisted throughout the 72.hour study in all patients. 
Conclusion: Whole blood aggregometw may prove to be a useful tool in detecting aspirin 
resistance. Using this method, we have determined that a 24.hour dosing intewal may be 
insufficient in mamtaining the antiplatelet effects of aspirin in a significant number of 
patients. In these patients, twice daily dosing of aspirin may be needed to maintain thera- 
peutic efficacy. Future studies are needed ln patients with cardiovascular disease to 
identify the prevalence of aspirin resistance in this population. 
1009-l 52 Demographic and Clinical Predictors of Excessive 
Anticoagulation Following Initiation of Warfarin 
Therapy 
Henock Saint-Jacques, Anne S. Hellkamp, David E. Kandzari, Christopher M. O’Connor, 
Robert M. Califf, Valentin Fuster. Stephen L. Kopecky, Anatoly Langer, Patrick T. 
O’Gara. David A. Vorchheimer, Robert A. Harrington. Duke Clinical Research Institute, 
Durham, NC, Duke University Medical Center, Durham, NC 
Background: Anticoagulant therapy with warfarin has established efficacy in the preven- 
tion of thromboembolic events. However, its potential benefits are limited by the risk of 
excessive antIcoagulatIon and subsequent serious or fatal hemorrhage. We sought to 
identify patient characteristics that predict excessive international normakzed ratio (INR) 
response after initiation of a uniform warfarin dosing regimen. Methods:Among patients 
(pts) in the Coumadin Aspirin Reinfarction Study (CARS) who were randomized to treat- 
ment with warfarin 3mg daily, excessive INR response was defined as INR >4.0 after one 
week of therapy. The dose of wariarin was fixed, and INR measurements were per- 
formed at the end of first week of therapy by a core laboratory using the same thrombo- 
plastin reagent (International Sensitivity Index, lSl=O.97). A logistic regression model was 
used to assess the relationship of baseline characterlstlcs with excessive INR response. 
Results: Out of 2,980 treated pts, 167 (5.6%) had an INR >4.0. Pts with excessive INR 
had significantly lower body weight or were older, of Asian ethnicity, or on fibrate therapy. 
Blacks had a much lower risk of excessive INR than other races. 
Variable P Odds Ratio (95% Confidence Interval) 
Weight 0.0001 1.16(1.12,1.25)for10Ibsdecrease 
Asian O.OOOl 5.06 (2.51, 10.19) 
Age 0.0001 1.36 (1.17, 1.59) for 10 years ~ncraase 
Black 0.019 0.094 (0.013, 0.68) 
Fibrate therapy 0.048 2.44 (1.01,5.92) 
Conclusion: These findings identify important patlent characteristics that are predictive 
of excessive anticoagulation despite modest doses of waiiarin and emphasize the recog- 
nition of high-risk clmical features. Such individuals may require more intensive monltor- 
ing and counselmg during warfarin therapy. 
1009-l 53 Unpredicted Amiodarone and Warfarin Interaction at the 
17th to 20th Week After the Initiation of Amiodsrone 
Yun Lu Luanne F. Sojka, Katie A. Won. Brenda J. Nelson, Douglas J. Rausch. Richard -I 
W. Asinger, Hennepin County Medical Center, Mtnneapolis, MN 
Background: Amiodarone and warfarin interact and warfarin dose is reduced when ami- 
odarone is initiated. Whether further adjustments in warfarin dosage can be anticipated is 
unclear. 
Objective: To determine whether and when adjustment of warfarin dosage after Initiation 
of amiodarone is needed. 
Method: We retrospectwely reviewed Anticoagulation Clinic patbents who initiated amio- 
darone while on warfarin therapy to determine the timing of amlodarone and wariarin 
interactions. INR readings were analyzed for 40 weeks after initiation of amiodarone. 
INRs >5.0 were defined as Grade I interactions; INR > upper target but < 5.0 were 
defined as grade II interactions. 
Results Of 524 patients, 24 had amiodarone started while on wariarin. Fourteen had 
their warfarin dose reduced when amiodarone was started. After the initiation of amio- 
darone, Grade I or II INR elevations were observed in 47% (41/87) of clinic visits during 
the first 8 weeks and 53% (20/38) from the lFh week to 20’” week. There were 8%(7187) 
grade 1 interactions observed during the first 8 weeks and 13% (5/38) Grade I interac- 
tions from week I? to week 20’” (see figure). 
Conclusions Amiodarone and wariarin interaction was bimodal with peaks in INR dur- 
ing the first two months and during the 17’h-20’h weeks after initiation of amiodarone. In 
addition to warfarin dose adjustment during initiation of amlodarone. more frequent INR 
checks may also be necessary 17 to 20 weeks later. 
